Pharmaceutical Glass Packaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Vials (Small vials, Large vials), Bottles(Small bottles, Large bottles), Cartridges & Syringes, Ampoules), By Drug Type (Generic, Branded, Biologic), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 21.07 Billion
CAGR (2026-2031)	5.76%
Fastest Growing Segment	Bottles
Largest Market	North America
Market Size (2031)	USD 29.48 Billion

Market Overview

The Global Pharmaceutical Glass Packaging Market will grow from USD 21.07 Billion in 2025 to USD 29.48 Billion by 2031 at a 5.76% CAGR. Pharmaceutical glass packaging is defined as the specialized manufacturing of primary containment solutions, including vials, ampoules, cartridges, and syringes, fabricated from borosilicate or soda-lime glass to ensure drug sterility and chemical stability. The market is fundamentally driven by the escalating global prevalence of chronic diseases requiring injectable therapies and the robust expansion of the generic medicine sector, which necessitates reliable, regulatory-compliant storage. These core drivers, distinct from transient market trends, underscore the critical reliance on glass for its superior impermeability and chemical inertness, qualities that are essential for preserving complex biologics and vaccines against environmental contaminants.

Despite this growth trajectory, the market encounters a substantial challenge in the form of material fragility, as glass breakage during high-speed fill-finish operations and transportation increases operational costs and safety risks compared to polymer alternatives. Nevertheless, the sector maintains strong economic momentum in key high-tech manufacturing regions. Reflecting this resilience, according to the Bundesverband Glasindustrie e.V., in 2024, the utility and special glass industry, a critical segment for pharmaceutical applications, achieved a revenue growth of 6.4 percent to reach EUR 1.82 billion.

Key Market Drivers

Rising Demand for Biologics and Biosimilars Requiring Specialized Glass is fundamentally reshaping the market's value chain by necessitating advanced containment solutions. Unlike traditional small-molecule drugs, complex biologics such as monoclonal antibodies and GLP-1 agonists differ significantly in their sensitivity to surface interactions, requiring the use of high-quality Type I borosilicate glass to prevent delamination and ensure chemical stability. This requirement has spurred a transition from standard commoditized vials to high-value solutions (HVS), including prefilled syringes and coated cartridges, which offer superior inertness and break resistance. This shift towards premium, specialized containment is evident in the financial performance of major industry players who are pivoting their portfolios to serve this segment. For instance, according to SCHOTT Pharma, December 2024, in the 'Annual Report 2024', the company's revenue from high-value solutions, driven by demand for injectable drugs, increased by 22 percent to account for 55 percent of its total fiscal revenue.

Rapid Growth of Pharmaceutical Markets in Emerging Economies acts as a critical volume driver, balancing the value-driven growth of developed markets. Countries such as India and China are aggressively expanding their domestic pharmaceutical manufacturing capabilities, supported by government mandates for supply chain localization and the robust expansion of the generic injectables sector. This geographic diversification compels global glass manufacturers to establish local production hubs to mitigate supply chain risks and reduce lead times for regional customers. A notable example of this trend is the strategic expansion in South Asia; according to Chemindigest, September 2025, in the article 'Corning and SGD Pharma Invest Funds in Telangana Glass Tubing Facility', Corning Incorporated and SGD Pharma inaugurated a joint venture facility in India with a combined investment of INR 500 crore to manufacture pharmaceutical-grade borosilicate glass tubing. Such investments underscore the industry's continued economic momentum. According to Gerresheimer AG, in February 2025, the consolidated group maintained a strong growth trajectory, achieving total revenues of EUR 2.04 billion for the financial year 2024.

Download Free Sample Report

Key Market Challenges

The primary impediment to the expansion of the pharmaceutical glass packaging sector is the inherent fragility of the material. Unlike durable polymer substrates, glass containers are susceptible to fracture during rigorous high-speed fill-finish processes and logistical handling. This breakage results in the immediate loss of high-value drug formulations and necessitates costly production stoppages for line clearance, significantly elevating operational expenses. Consequently, manufacturers face heightened liability risks when transporting sensitive biologics, compelling them to limit glass usage to essential applications where chemical inertness is non-negotiable.

The economic impact of this vulnerability is evident in the market's volume dynamics, where glass struggles to compete with shatter-resistant alternatives in non-specialized segments. The risk of particulate contamination from micro-cracks further complicates regulatory compliance, restricting adoption rates for mass-market generic injectables. Highlighting this volume constraint, according to the Glass Packaging Institute, in 2024, the shipment share for the combined cosmetics, pharmaceutical, and toiletries category represented less than 1 percent of the total United States glass container market. This statistic illustrates how physical limitations confine the material to a high-value niche, preventing broader volume dominance.

Key Market Trends

Accelerating Adoption of Sterile Ready-to-Use (RTU) Glass Vials is streamlining manufacturing by eliminating in-house washing and sterilization. This trend allows fill-finish lines to handle smaller batch sizes with greater flexibility, reducing total cost of ownership compared to bulk processing. By decoupling packaging preparation from drug filling, RTU platforms minimize contamination risks, prompting a decisive shift toward pre-sterilized systems. Highlighting this transition, according to Stevanato Group, March 2024, in the 'Fourth Quarter and Full Year 2023 Financial Results', revenue from the high-value solutions segment, which includes sterile containment systems, increased to account for 34 percent of the company's total fiscal revenue.

The Shift Toward Lightweight Glass Designs to Support Sustainability Goals is prioritizing carbon reduction through optimized geometries and recycled materials. Manufacturers are engineering lighter vials that require less energy to melt and transport, directly addressing Scope 3 emission targets. This movement validates eco-friendly glass compositions that maintain chemical stability while meeting corporate ESG mandates. The scale of this adoption is measurable; according to Bormioli Pharma, April 2024, in the 'ESG Report 2023', the company successfully increased the share of sustainable materials in its sold products to reach 45 percent, marking a significant year-over-year expansion.

Segmental Insights

Based on recent industry analysis, the Bottles segment is currently positioned as the fastest-growing category within the Global Pharmaceutical Glass Packaging Market. This accelerated expansion is primarily driven by the rising global consumption of generic liquid medications, such as syrups and suspensions, particularly in emerging economies. Glass bottles are increasingly favored for their superior chemical inertness, which ensures the stability of sensitive formulations by preventing container-drug interactions. Furthermore, manufacturers are prioritizing these containers to comply with rigorous safety standards from regulatory bodies like the U.S. Food and Drug Administration, ensuring product purity and extended shelf life.

Regional Insights

North America maintains a dominant position in the global pharmaceutical glass packaging market, driven by a well-established pharmaceutical manufacturing infrastructure and high healthcare expenditure. The region experiences strong demand for sterile injectables and biologic drugs, which require chemically stable glass containers such as vials and ampoules. Additionally, strict guidelines from the United States Food and Drug Administration regarding packaging safety and drug compatibility enforce the widespread adoption of high-quality glass solutions. This regulatory environment, supported by a robust generic drug sector, secures North America's status as the leading regional market.

Recent Developments

• In October 2024, Nipro PharmaPackaging launched its new D2F (Direct-to-Fill) glass vials, which are powered by Stevanato Group’s EZ-fill technology. These ready-to-use borosilicate glass vials are washed, depyrogenated, and sterilized, allowing pharmaceutical companies to integrate them directly into aseptic fill-finish processes without additional preparation steps. The product was designed to meet the rigorous quality standards of the industry and to support the increasing demand for high-quality, efficient packaging solutions for sensitive injectable drugs.
• In October 2024, SGD Pharma introduced a new range of siliconized molded glass vials at the CPHI Milan exhibition to address the needs of sensitive, aggressive, and viscous drug formulations. The company’s internal siliconization process applies a micro-layer of silicone to the internal surface of the vials, which enhances product recovery and minimizes interaction between the drug and the glass container. This launch expanded the company's portfolio of sustainable and high-performance packaging solutions, offering improved functionality for therapeutic areas such as veterinary and oral medications.
• In September 2024, Schott Pharma, Gerresheimer, and Stevanato Group announced the formation of the "Alliance for RTU" to promote the global adoption of ready-to-use (RTU) vials and cartridges in the pharmaceutical industry. The collaboration aims to accelerate the shift from bulk to sterilized, ready-to-fill glass packaging, which improves filling line efficiency, reduces total cost of ownership, and enhances patient safety by minimizing glass-to-glass contact. Through this strategic alliance, the three major packaging companies intend to standardize RTU solutions and facilitate faster time-to-market for drug developers.
• In March 2024, Bormioli Pharma announced the expansion of its manufacturing capabilities to produce Type I Glass expansion 33 vials at its European facilities. This operational development was implemented to specifically meet the regulatory standards and growing supply requirements of the North American pharmaceutical market. By adapting its production processes to include this specific glass type, the company aimed to strengthen its position as a global partner and ensure a robust supply chain for its United States customers requiring high-quality borosilicate glass vials.

Key Market Players

• Corning Incorporated
• Heartsine Technologies, Inc.
• Nipro Corporation
• SGD S.A.
• Stoelzle Oberglas GmbH
• Bormioli Pharma S.p.A.
• West Pharmaceutical Services, Inc.
• Schott AG
• Gerresheimer AG
• Shandong Pharmaceutical Glass Co., Ltd.
• Beatson Clark
• Ardagh Group S.A
• Arab Pharmaceutical Glass Co.
• Piramal Enterprises Ltd.
• Şişecam Group
• Owens-Illinois, Inc.

By Product	By Drug Type	By Region
Vials (Small vials, Large vials) Bottles(Small bottles, Large bottles) Cartridges & Syringes Ampoules	Generic Branded Biologic	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pharmaceutical Glass Packaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pharmaceutical Glass Packaging Market, By Product:

• Vials (Small vials, Large vials)
• Bottles(Small bottles, Large bottles)
• Cartridges & Syringes
• Ampoules

• Pharmaceutical Glass Packaging Market, By Drug Type:

• Generic
• Branded
• Biologic

• Pharmaceutical Glass Packaging Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE